Regeneron Pharmaceuticals, Inc. (REGN) Stock
Regeneron stock price chart
REGN stock quote & key statistics
Regeneron annual financials
Income statement →| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $14.34B | $4.50B | $44.38 |
| FY2024 | $14.20B | $4.41B | $45.64 |
| FY2023 | $13.12B | $3.95B | $43.78 |
| FY2022 | $12.17B | $4.34B | $44.96 |
| FY2021 | $16.07B | $8.08B | $74.78 |
Fiscal year ending December 31. Source: company filings via EODHD.
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a pioneering biotechnology company engaged in the discovery, development, and commercialization of transformative medicines worldwide. Established in 1988 and headquartered in Tarrytown, New York, Regeneron is renowned for its innovative products that address a wide spectrum of diseases. The company's portfolio includes EYLEA, which targets conditions such as neovascular age-related macular degeneration and diabetic retinopathy, and Dupixent, an advanced treatment for atopic dermatitis and asthma across both adult and pediatric populations. Additionally, Regeneron's groundbreaking REGEN-COV therapy has been pivotal in combating COVID-19, underscoring its commitment to addressing global health challenges.
Regeneron Pharmaceuticals, Inc. not only delivers critical treatments but also continuously pushes the boundaries of biotechnology with ongoing research and development initiatives. Beyond its commercial successes, the company maintains a robust pipeline of product candidates spanning areas such as eye diseases, allergic and inflammatory conditions, cardiovascular disorders, infectious diseases, and rare genetic conditions. This breadth of focus is supported by strategic collaborations with industry leaders like Sanofi, Bayer, and Roche, as well as partnerships with government entities and academic institutions, reinforcing Regeneron's role as a leader in biopharmaceutical innovation.
Driven by a mission to improve patient outcomes through scientific excellence and technological innovation, Regeneron Pharmaceuticals, Inc. remains at the forefront of biomedical research. With a steadfast dedication to advancing healthcare solutions, the company continues to redefine possibilities in treating cancer, pain management, hematologic disorders, and beyond, shaping the future of medicine worldwide.
Regeneron stock FAQ
What is the Regeneron stock ticker symbol?
Regeneron Pharmaceuticals, Inc. trades on the NASDAQ under the ticker symbol REGN.
What sector and industry is Regeneron in?
Regeneron Pharmaceuticals, Inc. is classified in the Healthcare sector, Biotechnology industry.
How many employees does Regeneron have?
Regeneron Pharmaceuticals, Inc. has about 15,410 full-time employees.
What were Regeneron's revenue and earnings last fiscal year?
Regeneron reported revenue of $14.34B and net income of $4.50B in fiscal 2025, with earnings per share of $44.38. Revenue grew 1.0% from the prior year.
Is Regeneron in the Nasdaq-100?
Yes. Regeneron Pharmaceuticals, Inc. (REGN) is a component of the Nasdaq-100 index, which tracks the largest non-financial companies listed on the Nasdaq Stock Market.
Is Regeneron in the S&P 500?
Yes. Regeneron Pharmaceuticals, Inc. (REGN) is a component of the S&P 500, the index of 500 leading U.S. companies widely used as a benchmark for the U.S. stock market.
Is Regeneron in the Russell 1000?
Yes. Regeneron Pharmaceuticals, Inc. (REGN) is a component of the Russell 1000, which tracks roughly the 1,000 largest U.S. companies.
When did Regeneron go public?
Regeneron stock began trading on April 2, 1991.